C228Y MUTATION WITH IRON OVERLOAD SYNDROME IN A PATIENT WITH CHRONIC HEPATITIS C

Article Sidebar

PDF (Russian)
Issue:
Section:
CASE HISTORY
Published:
2026-09-30

Main Article Content

Alexandra Valerievna Morozova
Novokuznetsk State Institute for Further Training of Physicians, 654005, Novokuznetsk, Stroiteley Pr., 5
Olga Alexandrovna Morozova
Novokuznetsk State Institute for Further Training of Physicians, 654005, Novokuznetsk, Stroiteley Pr., 5
Nikolay Andreevich Bichan
Novokuznetsk State Institute for Further Training of Physicians, 654005, Novokuznetsk, Stroiteley Pr., 5

Abstract

A clinical case of hereditary hemochromatosis (NHC) in combination with chronic viral hepatitis C at the stage of decompressed cirrhosis of the liver is presented. Clinical manifestations of NGC with a progressive course, which was facilitated by hepatitis C virus infection, were shown. The importance of timely diagnosis of concomitant liver pathology (in this case, NHC and hepatitis C viral infection) for effective treatment, improving the quality of life and increasing its duration was demonstrated.

Keywords

hemochromatosis, HFE mutation, iron overload syndrome, viral hepatitis C, ferritin

Author Biographies

Alexandra Valerievna Morozova,

candidate of medical sciences, docent of the department of therapy and occupational pathology

Olga Alexandrovna Morozova,

doctor of medical sciences, docent, professor of the department of therapy and occupational pathology

Nikolay Andreevich Bichan,

doctor of medical sciences, professor, head of the department of therapy and occupational pathology

Article Details

Information about financing and conflict of interests

The study had no sponsorship.
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
© Alexandra Valerievna Morozova, Olga Alexandrovna Morozova, Nikolay Andreevich Bichan, 2026


Creative Commons License  This work is licensed under a Creative Commons Attribution 4.0 License.

How to Cite

Morozova, A. V., Morozova, O. A., & Bichan, N. A. (2026). C228Y MUTATION WITH IRON OVERLOAD SYNDROME IN A PATIENT WITH CHRONIC HEPATITIS C. Medicine in Kuzbass, 25(3), 156-159. https://mednauki.ru/index.php/MK/article/view/1556

References

1. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. Natural history and predictors of disease cseverity in chronic hepatitis C. J Hepatjl. 2006; 44 (Suppl.): S19-24. doi: 10.1016/j.jhep.2005.11.009

2. Fujita N., Sugimoto R., Urawa N, Araki J, Mifuji R, Yamamoto M, et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2007; 22(11): 1886-1893. doi: 10.1111/j.1440-1746.2006.04759.x

3. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992; 102(6): 2108-2113. doi: 10.1016/0016-5085(92)90339-z

4. Eremina E.Yu. Gemochromatoz v praktike klinicista. 2015; 1(36): 74-78. (Еремина Е.Ю. Гемохроматоз в практике клинициста //Медицинский альманах. 2015. № 1(36). С. 74-78.)

5. Bassett S, Bisceglie AM, Bacon BR, Sharp RM, Govindarajan S, Hubbard GB, et al. Effects of iron loading on pathogenicity in hepatitis C virusinfected chimpanzees. Heрatology. 1999; 29(6): 1884-1892. doi: 10.1002/hep.510290623

6. Tandon N, Thakur V, Guptan RK, Sarin SK. Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease. Br J Nutr. 2000; 83(3): 235-239. doi: 10.1017/s0007114500000301

7. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology. 2006; 130(7): 2087-2098. doi: 10.1053/j.gastro.2006.02.060

8. Guyader D, Thirouard AS, Erdtmann I, Rakba N, Jacquelinet S, Danielou H, et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol. 2007; 46(4): 587-595. doi: 10.1016/j.jhep.2006.09.021

9. Sumida Y., Kanemasa K., Fukumoto K, Yoshida N, Sakai K. Effects of dietary iron reduction versus phlebotomy in patients with hepatitis C: Results from a randomized, controlled trial on 40 Japanese patients. Intern Med. 2007; 46(10): 637-642. doi: 10.2169/internalmedicine.46.6085

10. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gasrtroenterol. 2007; 42(10): 830-836. doi: 10.1007/s00535-007-2095-z

11. Klyaritskaya IL, Tsapyak TA, Iskova IA, Shelikhova EO, Krivoy VV, Maksimova EV. Hemochromatosis: the current state of the problem from the standpoint of clinical guidelines, 2022. Crimean Journal of Internal Diseases. 2022; 4: 22-29. Russian (Кляритская И.Л., Цапяк Т.А., Иськова И.А., Шелихова Е.О., Кривой В.В., Максимова Е.В. Гемохроматоз: Современное состояние проблемы с позиций клинических рекомендаций, 2022 г. //Крымский терапевтический журнал. 2022. № 4. С. 22-29.)

12. Tung BY, Emond MY, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: Relationship with HFE mutations. Gastroenterology. 2003; 124(2): 318-326. doi: 10.1053/gast.2003.50046

13. Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int. 2004; 24(4): 285-294. doi: 10.1111/j.1478-3231.2004.0928.x

Downloads

Download data is not yet available.